http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 09:26:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Oct+15/27191075.html si-local-file:///var/storage/secattach/20261015/27191075.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Oct+15/27191075.html Thu, 15 Oct 2026 09:26:00 -0400 AAPG http://www.streetinsider.com/New+Coverage/Citi+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/27182855.html <p>Citi analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $46.00.</p><p>For an analyst ratings summary and ratings history on Ascentage Pharma Group <a href="http://www.streetinsider.com/rating_history.php?q=AAPG">click here</a>. For more ratings news on Ascentage Pharma Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AAPG&amp;type=analyst">click here</a>.</p><p>Shares of Ascentage Pharma Group closed at $15.06 yesterday.</p> http://www.streetinsider.com/New+Coverage/Citi+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/27182855.html Wed, 14 Oct 2026 05:01:47 -0400 AAPG http://www.streetinsider.com/Hot+New+Coverage/Citi+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/27182855.html <p>Citi analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $46.00.</p><p>For an analyst ratings summary and ratings history on Ascentage Pharma Group <a href="http://www.streetinsider.com/rating_history.php?q=AAPG">click here</a>. For more ratings news on Ascentage Pharma Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AAPG&amp;type=analyst">click here</a>.</p><p>Shares of Ascentage Pharma Group closed at $15.06 yesterday.</p> http://www.streetinsider.com/Hot+New+Coverage/Citi+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/27182855.html Wed, 14 Oct 2026 05:01:47 -0400 AAPG http://www.streetinsider.com/New+Coverage/Citizens+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Market+Outperform/27175803.html <p>Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating and a price target of $35.00.</p><p>The analyst comments: “AAPG is a $1,375M market cap commercial-stage, multinational biotechnology company focused on targeted therapies in oncology. AAPG successfully marries expertise in pharmacology and international clinical development strategy and is aiming at high-value indications. We believe key Phase 3 data in MDS (2027) and CML (2027) can provide significant value, which are derisked through approvals in China.</p><p>Ascentage Pharma successfully marries expertise in pharmacology and clinical development strategy. 1) Me-better vs. Me-too: AAPG leverages expertise in chemical http://www.streetinsider.com/New+Coverage/Citizens+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Market+Outperform/27175803.html Tue, 13 Oct 2026 03:08:34 -0400 AAPG http://www.streetinsider.com/Analyst+Comments/Citizens+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Market+Outperform/27175803.html <p>Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating and a price target of $35.00.</p><p>The analyst comments: “AAPG is a $1,375M market cap commercial-stage, multinational biotechnology company focused on targeted therapies in oncology. AAPG successfully marries expertise in pharmacology and international clinical development strategy and is aiming at high-value indications. We believe key Phase 3 data in MDS (2027) and CML (2027) can provide significant value, which are derisked through approvals in China.</p><p>Ascentage Pharma successfully marries expertise in pharmacology and clinical development strategy. 1) Me-better vs. Me-too: AAPG leverages expertise in chemical http://www.streetinsider.com/Analyst+Comments/Citizens+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Market+Outperform/27175803.html Tue, 13 Oct 2026 03:08:34 -0400 AAPG http://www.streetinsider.com/Analyst+PT+Change/Ascentage+Pharma+Group++%28AAPG%29+PT+Lowered+to+%2433+at+JPMorgan/27164127.html JPMorgan analyst Brian Cheng lowered the price target on Ascentage Pharma Group (NASDAQ: AAPG) to $33.00 (from $46.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Ascentage+Pharma+Group++%28AAPG%29+PT+Lowered+to+%2433+at+JPMorgan/27164127.html Thu, 08 Oct 2026 08:10:54 -0400 AAPG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Sep+28/27116582.html si-local-file:///var/storage/secattach/20260929/27116582.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Sep+28/27116582.html Tue, 29 Sep 2026 06:01:00 -0400 AAPG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Sep+17/27073223.html si-local-file:///var/storage/secattach/20260917/27073223.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Sep+17/27073223.html Thu, 17 Sep 2026 08:30:00 -0400 AAPG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577